
'Are you guys out of virology?': Not hardly, says Gilead execs, as they buy a late-stage drug company for $1.7B
Gilead has turned the spotlight in M&A and BD to cancer since Dan O’Day took the top spot at the company. But today, it’s virology’s turn to take center stage.
The CEO has struck a deal to buy out Germany’s MYR GmbH, a privately held biotech which has an advanced drug for hepatitis delta virus that fits well with their focus on hepatitis B, for $1.7 billion. Most of that is in cash, with $360 million on the table for an FDA approval.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.